Tuesday, 18 Jun 2019

You are here

Might IL-17 Inhibition Be Effective in RA?

Interleukin 17 (IL-17) inhibitors are highly effective and FDA approved for use in psoriasis, psoriatic arthritis and ankylosing spondylitis. However, many of the initial trials were done in rheumatoid arthritis (RA) where it was projected to be effective, but was not.  A recent metanalysis examines whether IL-17 inhibition may be effective in two RA populations: biologic-naïve or tumor necrosis factor inhibitor inadequate responders (TNF-IR).

A systematic literature review identified 10 studies and 2499 RA patients who were treated with IL-17 inhibitors. 

Interestingly they found that IL-17 inhibition demonstrated significantly better (than placebo) ACR50 (RR = 1.71, 95% CI 1.23–2.38, P = 0.001) and ACR70 (RR = 2.63, 95% CI 1.10–6.25, P = 0.03) responses in biologic-naïve RA patients.

In biologic naive RA patients IL-17 inhibitors were no better than placebo (RR = 1.34, 95% CI 0.94–1.91, P = 0.11) at achieving ACR20 responses.

For TNF-IR, IL-17 inhibitors were effective in achieving ACR20 (RR = 1.67, 95% CI 1.40–2.00, P < 0.00001), ACR50 (RR = 1.94, 95% CI 1.43–2.63, P < 0.0001), and ACR70 (RR = 2.11, 95% CI 1.26–3.55, P = 0.005) compared to placebo.

Safety-wise IL-17 inhibitors did not show increased risk of any AEs by comparing to placebo in these trials.

IL-17 inhibitors were effective in the treatment of RA without increased risk of AEs, whether for biologic-naïve patients or TNF-IR.

While some anti-IL-17 trials in RA failed to meet their primary endpoints, these data suggest that there may be a subset of RA patients who can reliably achieve higher end responses (ACR20, ACR50) through IL-17 inhibition.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

EULAR 2019 - Day 1 Report

Here are a few of the highlights from day 1 EULAR in Madrid. 

Low Remission/LDA Rates with TNF inhibitors in Rheumatoid Arthritis

 

Analysis of Rheumatoid Arthritis patients enrolled and treated as part of the British Society for Rheumatology Biologics Registry shows that sustained remission or low disease activity state (LDA) on TNF inhibitor treatment is uncommon and that combing methotrexate with an anti-TNF increases the odds of sustained remission/LDA.

Proinflammatory Diets May Increase CRP and RA Onset

Despite the lack of good evidence, there has been great speculation about the role of diet in causing or alleviating inflammation. Now there's new research suggesting that proinflammatory diets can increase serum C-reactive protein levels and also the risk of rheumatoid arthritis onset.

Lung Disease in RA: Which Factors are Linked With Mortality?

Among patients with rheumatoid arthritis (RA) who had interstitial lung disease (ILD), the pattern of ILD did influence mortality, but other pulmonary factors also contributed, a meta-analysis suggested.

Opioids, SSRIs and Steroids Increase Fracture Risk in RA

Analysis of a large US observational rheumatoid arthritis (RA) patients finds that opioids, SSRIs and glucocorticoids were associated with increased risk of fracture in RA, whereas statins and TNFi had a decreased vertebral fracture risk.